Skip to main content
MedPathMedPath Home
Clinical Trials/ISRCTN48560305
ISRCTN48560305
Completed
未知

Are early and late cardiovascular risk markers in women with polycystic ovary syndrome increased with concomitant non-alcoholic steatohepatitis and can this be modified with liraglutide?

Hull and East Yorkshire Hospitals NHS Trust (UK)0 sites40 target enrollmentMay 22, 2012
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Overview

Phase
未知
Intervention
Not specified
Conditions
Not specified
Sponsor
Hull and East Yorkshire Hospitals NHS Trust (UK)
Enrollment
40
Status
Completed
Last Updated
9 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
May 22, 2012
End Date
TBD
Last Updated
9 years ago
Study Type
Interventional
Sex
Female

Investigators

Sponsor
Hull and East Yorkshire Hospitals NHS Trust (UK)

Eligibility Criteria

Inclusion Criteria

  • •Polycystic ovary syndrome (defined by the Rotterdam criteria) as 2 out of 3 of:
  • •1\. Oligo / anovulation
  • •2\. Clinical or biochemical evidence of hirsuitism, and/or
  • •3\. Polycystic ovaries on ultrasound and the exclusion of other disorders
  • •4\. Age 18\-45 years
  • •For normal controls:
  • •1\. Female, aged 18 \- 45
  • •2\. Body madd index (BMI) 30 \- 45
  • •3\. No current medical problems

Exclusion Criteria

  • •1\. Ketoacidosis
  • •2\. Severe gastrointestinal disease
  • •3\. Hypothyroidism
  • •4\. Subjects taking regular medications associated with high risk of hepatotoxicity like isoniazid and methotrexate
  • •5\. Not using a reliable method of contraception
  • •6\. Patients not allowing disclosure to their GP's
  • •7\. History of pancreatitis
  • •8\. Heart Failure
  • •9\. Chronic renal failure (creatinine clearance less than 60 ml/min or plasma creatinine \>150 umol/L)
  • •10\. Pregnancy or breastfeeding women

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Not Applicable
Are early and late cardiovascular risk markers in women with Polycystic Ovary Syndrome increased with concomitant Nonalcoholic Steatohepatitis and can this be modified with Exenatide? - CV risk in PCOS and NASH
EUCTR2008-006928-55-GBHull and East Yorkshire NHS Trust
Active, not recruiting
Phase 1
Are early and late cardiovascular risk markers in women with Polycystic Ovary Syndrome increased with concomitant Nonalcoholic Steatohepatitis and can this be modified with Liraglutide?Polycystic Ovary Syndrome Non-alcoholic SteatohepatitisMedDRA version: 12.0 Level: LLT Classification code 10065161 Term: Polycystic ovarian syndromeMedDRA version: 12.0 Level: LLT Classification code 10053219 Term: Non-alcoholic steatohepatitis
EUCTR2009-015927-94-GBHull and East Yorkshire NHS Trust
Completed
Not Applicable
Are early and late cardiovascular risk markers in women with polycystic ovary syndrome (PCOS) increased with concomitant non-alcoholic steatohepatitis (NASH) and can this be modified with exenatide?Polycystic ovary syndrome, non-alcoholic steatohepatitisNutritional, Metabolic, EndocrineOvarian dysfunction
ISRCTN81902209Hull and East Yorkshire Hospitals NHS Trust (UK)20
Completed
Not Applicable
Early detection of cardiovascular risk factors after pregnancy complicated by hypertensive disorders or spontaneous preterm birthcardiovascular disease after hypertensive disorders in pregnancy or after spontaneous preterm birth100192801002690810057166
NL-OMON45089Vrije Universiteit Medisch Centrum687
Completed
Not Applicable
Biomarkers and cardiovascular risk in disease models of non-alcoholic fatty liver disease
NL-OMON48654Medisch Universitair Ziekenhuis Maastricht85